Trial Profile
Study of the evolution of Th17 immune response in patients with rheumatoid arthritis treated with tocilizumab and after failure of other therapies [Etude de l'evolution de la reponse immunitaire Th17 chez des patients atteints de polyarthrite rhumatoide et traites par tocilizumab apres echec des autres therapies]
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2012
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Pharmacogenomic
- 28 Jun 2012 Planned End Date changed to 31 Oct 2011.
- 27 Jun 2011 New trial record